Hoerauf Hans, Roider Johann, Kobuch Karin, Laqua Horst
Department of Ophthalmology, Medical University Lübeck, Lübeck, Germany.
Retina. 2005 Jun;25(4):479-88. doi: 10.1097/00006982-200506000-00014.
To investigate the safety and performance of perfluorohexylethan (O62), a partially fluorinated alkane, as an intraoperative tool and heavy ocular endotamponade in complex vitreoretinal surgery.
In a prospective clinical study, O62 was used as a postoperative ocular endotamponade in 11 eyes of 11 patients after pars plana vitrectomy for the following inferior pathologic conditions, proliferative vitreoretinopathy (n = 8), rhegmatogenous retinal redetachment with inferior tears (n = 1), and inferior giant tear (n = 2). The median duration of the O62 tamponade was 43 days (range, 17-55 days), and the median follow-up period after removal of the tamponade was 16 months.
The initial postoperative retinal attachment rate was 100%. In 7 of 11 eyes, the retina remained attached during the O62 tamponade and after its removal. During the tamponade period, no epiretinal membrane formation or macular pucker was observed in these seven eyes. Recurrent retinal detachments with proliferative vitreoretinopathy developed in 4 of 11 eyes under the tamponade. The median follow-up after removal of O62 was 16 months. A secondary cataract developed in all five phakic eyes. Severe emulsification was noted in all patients starting in the second week after surgery causing a decrease of visual acuity and a significantly reduced funduscopic view. In the early postoperative period, a marked inflammatory reaction in the anterior segment was seen in all patients. Slightly whitish precipitates were noted in 2 of 11 eyes. A transient increase in intraocular pressure up to 35 mmHg was observed in 2 of 11 eyes.
O62 showed good tamponade properties for the inferior retina over 6 weeks. However, its use as a postoperative retinal tamponade is limited by its severe emulsification propensity and unclear inflammatory potential.
研究全氟己基乙烷(O62),一种部分氟化的烷烃,作为术中工具和复杂玻璃体视网膜手术中重度眼内填充剂的安全性和性能。
在一项前瞻性临床研究中,11例患者的11只眼在玻璃体切割术后,将O62用作术后眼内填充剂,用于治疗以下下方病理性情况:增生性玻璃体视网膜病变(n = 8)、伴有下方裂孔的孔源性视网膜脱离(n = 1)和下方巨大裂孔(n = 2)。O62填充的中位持续时间为43天(范围17 - 55天),填充剂取出后的中位随访期为16个月。
术后初始视网膜附着率为100%。11只眼中有7只眼在O62填充期间及取出后视网膜保持附着。在这7只眼中,填充期间未观察到视网膜前膜形成或黄斑皱缩。11只眼中有4只眼在填充期间发生伴有增生性玻璃体视网膜病变的复发性视网膜脱离。O62取出后的中位随访时间为16个月。所有5只晶状体眼均发生了后发性白内障。所有患者在术后第二周开始均出现严重乳化,导致视力下降和眼底观察明显受限。术后早期,所有患者眼前节均出现明显炎症反应。11只眼中有2只眼出现轻微白色沉淀物。11只眼中有2只眼观察到眼压短暂升高至35 mmHg。
O62在6周以上对下方视网膜显示出良好的填充性能。然而,其作为术后视网膜填充剂的应用受到其严重乳化倾向和不明炎症潜能的限制。